{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "6177374",
  "DateCompleted": {
    "Year": "1982",
    "Month": "08",
    "Day": "14"
  },
  "DateRevised": {
    "Year": "2019",
    "Month": "05",
    "Day": "01"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "0267-0623",
      "JournalIssue": {
        "Volume": "284",
        "Issue": "6332",
        "PubDate": {
          "Year": "1982",
          "Month": "Jun",
          "Day": "19"
        }
      },
      "Title": "British medical journal (Clinical research ed.)",
      "ISOAbbreviation": "Br Med J (Clin Res Ed)"
    },
    "ArticleTitle": "Purified interferon as protection against rhinovirus infection.",
    "Pagination": {
      "StartPage": "1822",
      "EndPage": "1825",
      "MedlinePgn": "1822-5"
    },
    "Abstract": {
      "AbstractText": [
        "In a double-blind placebo-controlled study a preparation of human leucocyte interferon purified by affinity chromatography using a monoclonal antibody and applied by repeated nasal sprays reduced the incidence and severity of colds in volunteers challenged with human rhinovirus 9. Although interferon itself caused some symptoms, these were minor compared with the clinical colds. Interferon activity was still detectable in nasal washings as long as 26 hours after the last dose in about half the volunteers on active treatment."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Scott",
        "ForeName": "G M",
        "Initials": "GM"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Phillpotts",
        "ForeName": "R J",
        "Initials": "RJ"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Wallace",
        "ForeName": "J",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Secher",
        "ForeName": "D S",
        "Initials": "DS"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Cantell",
        "ForeName": "K",
        "Initials": "K"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Tyrrell",
        "ForeName": "D A",
        "Initials": "DA"
      }
    ],
    "PublicationTypeList": [
      "Clinical Trial",
      "Journal Article",
      "Randomized Controlled Trial"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Br Med J (Clin Res Ed)",
    "NlmUniqueID": "8302911",
    "ISSNLinking": "0267-0623"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "9008-11-1",
      "NameOfSubstance": "Interferons"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Administration, Intranasal"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Clinical Trials as Topic"
    },
    {
      "QualifierName": [
        "prevention & control"
      ],
      "DescriptorName": "Common Cold"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Double-Blind Method"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "therapeutic use"
      ],
      "DescriptorName": "Interferons"
    },
    {
      "QualifierName": [
        "microbiology"
      ],
      "DescriptorName": "Nose"
    },
    {
      "QualifierName": [
        "isolation & purification"
      ],
      "DescriptorName": "Rhinovirus"
    }
  ]
}